Publication|Articles|September 24, 2025 (Updated: September 24, 2025)
Supplements and Featured Publications
- Long-Acting Injectable Administration In Schizophrenia With Insights From Genoa Healthcare® Pharmacy
Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia
Listen
0:00 / 0:00
Advertisement
This educational resource was sponsored by Johnson & Johnson.
In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable antipsychotic programs, which are designed to help improve access and adherence to medications for people living with a severe and persistent mental illness like schizophrenia.
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
3
Active US Drug Shortages Rise for Third Straight Quarter
4
Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD
5